A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

BACKGROUND: DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented in the global pivotal CM study. METHODS: DRAGON study was conducted across 9 Asian coun...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shengyuan, Kim, Byung-Kun, Wang, Hebo, Zhou, Jiying, Wan, Qi, Yu, Tingmin, Lian, Yajun, Arkuszewski, Michal, Ecochard, Laurent, Wen, Shihua, Yin, Fangfang, Li, Zheng, Su, Wendy, Wang, Shuu-Jiun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676838/
https://www.ncbi.nlm.nih.gov/pubmed/36404301
http://dx.doi.org/10.1186/s10194-022-01514-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676838/
https://www.ncbi.nlm.nih.gov/pubmed/36404301
http://dx.doi.org/10.1186/s10194-022-01514-9

Ejemplares similares